about
Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective studyCurrent Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
How to select targeted therapy in renal cell cancer.
@en
How to select targeted therapy in renal cell cancer.
@nl
type
label
How to select targeted therapy in renal cell cancer.
@en
How to select targeted therapy in renal cell cancer.
@nl
prefLabel
How to select targeted therapy in renal cell cancer.
@en
How to select targeted therapy in renal cell cancer.
@nl
P2093
P356
P1433
P1476
How to select targeted therapy in renal cell cancer.
@en
P2093
P304
P356
10.1093/ANNONC/MDQ371
P478
21 Suppl 7
P577
2010-10-01T00:00:00Z